A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Vildagliptin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 01 Oct 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History